Skip to main content

Table 2 Early, late and total apoptosis in AML and ALL patients

From: Spontaneous apoptosis and BCL2 gene expression as predictors of early death and short overall survival in acute leukemia patients: a prospective, case cohort study

  Annxine V P Annexine&PI P Total apoptosis P
AML patients (n = 70)
 FAB
  APL* (n = 11) 4.2 (0.3–6.2) NS 5.4 (0.9–7.8) NS 6.3 (3.1–13.3) NS
  Non-APL (n = 59) 4.3 (0.3–13.6) 5.3 (0.6–17.1) 9.8 (1.7–19.3)
 Performance status
  0/1 (n = 33) 5.2 (0.3–9.5) NS 5.5 (0.6–14.6) NS 12.3 (2.9–18.5) NS
  2/3 (n = 37) 3.9 (1.0–13.6) 4.1 (0.6–17.2) 9.6 (1.7–19.3)
 Early death
  Yes (n = 20) 3.8 (1.0–6.9) NS 3.4 (0.7–7.6) 0.006 8.8 (1.7–12.5) 0.001
  No (n = 48) 4.5 (0.3–13.6) 5.6 (0.6–17.1) 12.4 (2.9–19.3)
ALL patients (n = 28)
 FAB
  B.ALL (n = 16) 9.1 (2.2–15.9) 0.001 13.4 (11.3–24.1) 0.001 21.8 (14.8–38.0) NS
  T.ALL (n = 12) 15.9 (13.8–18.6) 7.7 (5.9–9.1) 23.8 (20.5–27.4)
 Performance status
  0/1 (n = 18) 15.4 (13.5–18.6) 0.001 8.3 (5.9–24.1) NS 25.5 (20.5–38.0) 0.001
  2/3 (n = 10) 6.3 (2.2–9.3) 12.7 (11.3–13.8) 19.2 (14.8–22.4)
 Early death
  Yes (n = 5) 3.7 (3.1–8.5) 0.001 12.7 (11.3–13.1) NS 15.8 (14.8–22.3) 0.002
  No (n = 23) 14.6 (2.2–18.6) 9.1 (5.9–24.1) 24.0 (14.9–38.0)
  1. *Acute Promyelocytic Leukemia
  2. Two patients left hospital at the induction phase
  3. Mann–Whitney’s U test was used
  4. Significant P values are written in bold; NS, not significant